Zurich-based ImmunOs taps U.S.-EU syndicate for $74M series B, expands footprint

As ImmunOs advances its first immuno-oncology program toward the clinic, the Swiss university spinout has broadened its investor syndicate and international footprint by adding a bevy of U.S. investors to its $74 million series B round and opening an office in Maryland.

Samsara BioCapital, Lightspeed Venture Partners, and Gimv led the round for ImmunOs Therapeutics AG, building on its CHF15 million ($15.2 million) series A in late 2019. Early backers Pfizer Ventures, BioMed Partners, and Schroder Adveq also joined in the series B, along with new investors...